Advertisement

Cancer Immunity

  • Shi-Ming TuEmail author
Chapter
Part of the Cancer Treatment and Research book series (CTAR, volume 154)

Précis

The theory of a stem-cell origin of cancer and cancer immunity implies that certain tumor antigens must also be stem-cell antigens.

Keywords

Stem Cell Prostate Cancer Cancer Vaccine Objective Clinical Response Progenitor Stem Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Sell S, Pierce GB (1994) Maturation arrest of stem cell differentiation is a common pathway for the cellular origin of teratocarcinomas and epithelial cancers. Lab Invest 70:6–22PubMedGoogle Scholar
  2. 2.
    Penn I (1994) Depressed immunity and the development of cancer [review]. Cancer Detect Prev 18:241–252PubMedGoogle Scholar
  3. 3.
    Pfeffer PF (1999) Cancer in organ transplanted patients [in Norwegian]. Tidsskr Nor Laegeforen 119:3792–3794PubMedGoogle Scholar
  4. 4.
    Schröder J, Tiilikainen A, De la Chapelle A (1974) Fetal leukocytes in the maternal circulation after delivery. I. Cytological aspects. Transplantation 17:346–354CrossRefPubMedGoogle Scholar
  5. 5.
    Herzenberg LA, Bianchi DW, Schröder J et al (1979) Fetal cells in the blood of pregnant women: detection and enrichment by fluorescence-activated cell sorting. Proc Natl Acad Sci USA 76:1453–1455CrossRefPubMedGoogle Scholar
  6. 6.
    Thomas MR, Williamson R, Craft I et al (1994) Y chromosome sequence DNA amplified from peripheral blood of women in early pregnancy [letter]. Lancet 343:413–414CrossRefPubMedGoogle Scholar
  7. 7.
    Liégeois A, Escourrou J, Ouvré E et al (1977) Microchimerism: a stable state of low-ratio proliferation of allogeneic bone marrow. Transplant Proc 9:273–276PubMedGoogle Scholar
  8. 8.
    Bianchi DW, Zickwolf GK, Weil GJ et al (1996) Male fetal progenitor cells persist in maternal blood for as long as 27 years postpartum. Proc Natl Acad Sci USA 93:705–708CrossRefPubMedGoogle Scholar
  9. 9.
    Starzl TE, Demetris AJ, Murase N et al (1992) Cell migration, chimerism, and graft acceptance [review]. Lancet 339:1579–1582CrossRefPubMedGoogle Scholar
  10. 10.
    Drukker M, Katz G, Urbach A et al (2002) Characterization of the expression of MHC proteins in human embryonic stem cells. Proc Natl Acad Sci USA 99:9864–9869CrossRefPubMedGoogle Scholar
  11. 11.
    Rouas-Freiss N, Moreau P, Ferrone S et al (2005) HLA-G proteins in cancer: do they provide tumor cells with an escape mechanism? Cancer Res 65:10139–10144CrossRefPubMedGoogle Scholar
  12. 12.
    Paul P, Rouas-Freiss N, Khalil-Daher I et al (1998) HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance. Proc Natl Acad Sci USA 95:4510–4515CrossRefPubMedGoogle Scholar
  13. 13.
    Créput C, Durrbach A, Menier C et al (2003) Human leukocyte antigen-G (HLA-G) expression in biliary epithelial cells is associated with allograft acceptance in liver-kidney transplantation. J Hepatol 39:587–594CrossRefPubMedGoogle Scholar
  14. 14.
    Lila N, Amrein C, Guillemain R et al (2002) Human leukocyte antigen-G expression after heart transplantation is associated with a reduced incidence of rejection. Circulation 105:1949–1954CrossRefPubMedGoogle Scholar
  15. 15.
    Ugurel S, Rebmann V, Ferrone S et al (2001) Soluble human leukocyte antigen–G serum level is elevated in melanoma patients and is further increased by interferon-a immunotherapy. Cancer 92:369–376CrossRefPubMedGoogle Scholar
  16. 16.
    Huang W-C, Wu D, Xie Z et al (2006) b2-Microglobulin is a signaling and growth-promoting factor for human prostate cancer bone metastasis. Cancer Res 66:9108–9116CrossRefPubMedGoogle Scholar
  17. 17.
    Gough MJ, Melcher AA, Ahmed A et al (2001) Macrophages orchestrate the immune response to tumor cell death. Cancer Res 61:7240–7247PubMedGoogle Scholar
  18. 18.
    Peggs KS, Segal NH, Allison JP (2007) Targeting immunosupportive cancer therapies: accentuate the positive, eliminate the negative. Cancer Cell 12:192–199CrossRefPubMedGoogle Scholar
  19. 19.
    Morley A (1998) Quantifying leukemia [editorial]. N Engl J Med 339:627–629CrossRefPubMedGoogle Scholar
  20. 20.
    Hsueh EC, Essner R, Foshag LJ et al (2002) Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine. J Clin Oncol 20:4549–4554CrossRefPubMedGoogle Scholar
  21. 21.
    Eggermont AM, Suciu S, Ruka W et al (2008) EORTC 18961: Post-operative adjuvant ganglioside GM2-KLH21 vaccination treatment vs observation in stage II (T3-T4 N0M0) melanoma: 2nd interim analysis led to an early disclosure of the results [abstr]. In: Proceedings of the American Society of Clinical Oncology, Chicago, IL, May 30–June 3, 2008. Abstract 9004Google Scholar
  22. 22.
    Galligioni E, Quaia M, Merlo A et al (1996) Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus Calmette-Guèrin: five-year results of a prospective randomized study. Cancer 77:2560–2566CrossRefPubMedGoogle Scholar
  23. 23.
    Jonasch E, Wood C, Tamboli P et al (2008) Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: clinical findings. Br J Cancer 98:1336–1341CrossRefPubMedGoogle Scholar
  24. 24.
    Childs R, Chernoff A, Contentin N et al (2000) Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 343:750–758CrossRefPubMedGoogle Scholar
  25. 25.
    The Future II Study Group (2007) Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 356:1915–1927CrossRefGoogle Scholar
  26. 26.
    Small EJ, Schellhammer PF, Higano CS et al (2006) Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 24:3089–3094CrossRefPubMedGoogle Scholar
  27. 27.
    Urisman A, Molinaro RJ, Fischer N et al (2006) Identification of a novel gammaretrovirus in prostate tumors of patients homozygous for R462Q RNASEL variant. PLoS Pathog 2:e25CrossRefPubMedGoogle Scholar
  28. 28.
    Nissen C, Schubert J (2002) Seeing the good and bad in aplastic anemia: is autoimmunity in AA dysregulated or antineoplastic? Hematol J 3:169–175CrossRefPubMedGoogle Scholar
  29. 29.
    Tomer Y, Sherer Y, Shoenfeld Y (1998) Autoantibodies, autoimmunity and cancer [review]. Oncol Rep 5:753–761PubMedGoogle Scholar
  30. 30.
    Franzke A, Peest D, Probst-Kepper M et al (1999) Autoimmunity resulting from cytokine treatment predicts long-term survival in patients with metastatic renal cell cancer. J Clin Oncol 17:529–533, Erratum in J Clin Oncol 1999;17(4):1330PubMedGoogle Scholar
  31. 31.
    Dudley ME, Wunderlich JR, Robbins PF et al (2002) Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298:850–854CrossRefPubMedGoogle Scholar
  32. 32.
    Kaufman HL, DeRaffele G, Mitcham J et al (2005) Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma. J Clin Invest 115:1903–1912CrossRefPubMedGoogle Scholar
  33. 33.
    Phan GQ, Yang YC, Sherry RM et al (2003) Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 100:8372–8377CrossRefPubMedGoogle Scholar
  34. 34.
    Beck KE, Blansfield JA, Tran KQ et al (2006) Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 24:2283–2289CrossRefPubMedGoogle Scholar
  35. 35.
    Molldrem JJ, Komanduri K, Wieder E (2002) Overexpressed differentiation antigens as targets of graft-versus-leukemia reactions. Curr Opin Hematol 9:503–508CrossRefPubMedGoogle Scholar
  36. 36.
    Molldrem JJ, Lee PP, Wang C et al (2000) Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med 6:1018–1023CrossRefPubMedGoogle Scholar
  37. 37.
    Franssen CF, Tervaert JW, Stegeman CA et al (1996) c-ANCA as a marker of Wegener’s disease [letter]. Lancet 347:116CrossRefPubMedGoogle Scholar
  38. 38.
    Bories D, Raynal M-C, Solomon DH et al (1989) Down-regulation of a serine protease, myeloblastin, causes growth arrest and differentiation of promyelocytic leukemia cells. Cell 59:959–968CrossRefPubMedGoogle Scholar
  39. 39.
    Campbell CL, Jiang Z, Savarese DM et al (2001) Increased expression of the interleukin-11 receptor and evidence of STAT3 activation in prostate carcinoma. Am J Pathol 158:25–32PubMedGoogle Scholar
  40. 40.
    Weich NS, Wang A, Fitzgerald M et al (1997) Recombinant human interleukin-11 directly promotes megakaryocytopoiesis in vitro. Blood 90:3893–3902PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.The University of Texas M. D. Anderson Cancer CenterHoustonUSA

Personalised recommendations